The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult population.

Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven't responded to oral antidepressants.

Matt Price drove his 73-year-old father Stephen from their New Jersey home to a medical strip mall on the Jersey Shore, for ...

Duato discusses the split of the business, dealing with the scrutiny brought about by lawsuits, and 2025 priorities.

Gottlieb, who led the agency during the first Trump presidency, supports a reversion to an earlier interpretation of the 21st Century Cures Act.

Johnson & Johnson is normally a good buy for its dividend and the stability it offers. Over the past five years, however, the ...

For part 3 of our interview with Katie Abouzahr, MD, Johnson & Johnson Innovative Medicine, we discuss the favorable safety and efficacy profile of nipocalimab for generalized myasthenia gravis (gMG).

Johnson & Johnson has a strong business ... and a new law in the U.S. that gives Medicare the power to negotiate drug prices. The first round of negotiations will target three of the company's ...